Gigacloud Technology Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Gigacloud Technology Inc trades at $57.21 (market cap $2.02B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.95 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 12.5× Gigacloud Technology Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| GCT | RPRX | |
|---|---|---|
Market Cap | $2.02B | $25.27B |
Volume | 1,020,985 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $56.42 | $63.96 |
52-Week Low | $25.46 | $35.44 |
Typical Hold Time | 21 Days | 1 Days |
Enterprise Value | $2.14B | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
GCT trades at $57.02, up 1.89% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid profitability with 10.65% net margins and robust ROE of 32.34%. Recent news highlights institutional interest and European expansion driving growth.
Outlook remains positive with analyst consensus favoring buys (66.7%) and revenue projected to grow to $1.5B in 2026. Key risks include insider selling and competitive pressures in consumer discretionary sector. The stock trades at reasonable valuation multiples (P/E 13.44) with upside potential to consensus target of $32.50.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →